GB0107106D0 - Powder inhaler formulations - Google Patents

Powder inhaler formulations

Info

Publication number
GB0107106D0
GB0107106D0 GBGB0107106.7A GB0107106A GB0107106D0 GB 0107106 D0 GB0107106 D0 GB 0107106D0 GB 0107106 A GB0107106 A GB 0107106A GB 0107106 D0 GB0107106 D0 GB 0107106D0
Authority
GB
United Kingdom
Prior art keywords
powder inhaler
inhaler formulations
dosage forms
surface modification
pharmaceutical dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0107106.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to GBGB0107106.7A priority Critical patent/GB0107106D0/en
Publication of GB0107106D0 publication Critical patent/GB0107106D0/en
Priority to US10/085,972 priority patent/US20030007932A1/en
Priority to MXPA03008398A priority patent/MXPA03008398A/es
Priority to PCT/EP2002/002948 priority patent/WO2002080884A2/en
Priority to JP2002578923A priority patent/JP2004523594A/ja
Priority to AU2002316820A priority patent/AU2002316820A1/en
Priority to EP02745193A priority patent/EP1372610B1/en
Priority to CA2440010A priority patent/CA2440010C/en
Priority to AT02745193T priority patent/ATE556704T1/de
Priority to UY27218A priority patent/UY27218A1/es
Priority to US11/093,491 priority patent/US20050196346A1/en
Priority to US11/653,887 priority patent/US20080057003A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0107106.7A 2001-03-21 2001-03-21 Powder inhaler formulations Ceased GB0107106D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB0107106.7A GB0107106D0 (en) 2001-03-21 2001-03-21 Powder inhaler formulations
US10/085,972 US20030007932A1 (en) 2001-03-21 2002-02-28 Powder inhaler formulations
AT02745193T ATE556704T1 (de) 2001-03-21 2002-03-16 Pulverinhalator-formulierungen
JP2002578923A JP2004523594A (ja) 2001-03-21 2002-03-16 粉末吸入製剤
PCT/EP2002/002948 WO2002080884A2 (en) 2001-03-21 2002-03-16 Powder inhaler formulations
MXPA03008398A MXPA03008398A (es) 2001-03-21 2002-03-16 Formulaciones de polvos para inhalacion.
AU2002316820A AU2002316820A1 (en) 2001-03-21 2002-03-16 Powder inhaler formulations
EP02745193A EP1372610B1 (en) 2001-03-21 2002-03-16 Powder inhaler formulations
CA2440010A CA2440010C (en) 2001-03-21 2002-03-16 Powder inhaler formulations
UY27218A UY27218A1 (es) 2001-03-21 2002-03-20 Formulaciones de polvos para inhalación
US11/093,491 US20050196346A1 (en) 2001-03-21 2005-03-30 Powder inhaler formulations
US11/653,887 US20080057003A1 (en) 2001-03-21 2007-01-17 Powder inhaler formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0107106.7A GB0107106D0 (en) 2001-03-21 2001-03-21 Powder inhaler formulations

Publications (1)

Publication Number Publication Date
GB0107106D0 true GB0107106D0 (en) 2001-05-09

Family

ID=9911273

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0107106.7A Ceased GB0107106D0 (en) 2001-03-21 2001-03-21 Powder inhaler formulations

Country Status (10)

Country Link
US (3) US20030007932A1 (enExample)
EP (1) EP1372610B1 (enExample)
JP (1) JP2004523594A (enExample)
AT (1) ATE556704T1 (enExample)
AU (1) AU2002316820A1 (enExample)
CA (1) CA2440010C (enExample)
GB (1) GB0107106D0 (enExample)
MX (1) MXPA03008398A (enExample)
UY (1) UY27218A1 (enExample)
WO (1) WO2002080884A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN102688224A (zh) * 2003-04-14 2012-09-26 维克特拉有限公司 用于提高剂量效率的药物组合物和装置
SE0302665D0 (sv) 2003-10-07 2003-10-07 Astrazeneca Ab Novel Process
ITMI20040795A1 (it) * 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
EP3199164B1 (en) 2005-02-10 2020-03-18 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
DK1917253T3 (da) 2005-08-15 2015-03-30 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af betamimetika
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ピリジノン置換インダゾール
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
EP2476680B1 (en) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinone)-Substituted Pyridoindoles
EP2349224B1 (en) 2008-10-10 2017-05-10 Probelte Pharma, S.A. Orally administrable immunostimulant product for aquaculture
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US8673931B2 (en) 2009-01-26 2014-03-18 Abraham Fisher Bicyclic heterocyclic spiro compounds
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
EP3130396B1 (en) 2009-03-27 2021-03-17 Bend Research, Inc. Spray-drying process
TR200909788A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
EP2611530B1 (en) 2010-09-03 2019-01-16 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
US10105500B2 (en) 2012-05-09 2018-10-23 Virginia Commonwealth University Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions
ES2588902T3 (es) * 2012-05-14 2016-11-07 Boehringer Ingelheim International Gmbh Dispositivo para alojar un blíster de fármacos
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
PT3212169T (pt) 2014-10-31 2021-05-06 Bend Res Inc Processo para formar domínios ativos dispersos numa matriz
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
CN110996912A (zh) * 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US11786460B2 (en) * 2018-04-16 2023-10-17 Ioulia Tseti Pharmaceutical dry powder composition for inhalation comprising a thyroid hormone
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
EP3906233B1 (en) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL263733A (enExample) * 1960-04-19 1900-01-01
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4533542A (en) * 1983-08-22 1985-08-06 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6645644B1 (en) * 1996-10-17 2003-11-11 The Trustees Of Princeton University Enhanced bonding of phosphoric and phosphoric acids to oxidized substrates
US5874111A (en) * 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
JP2001517692A (ja) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
ES2192866T3 (es) * 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation

Also Published As

Publication number Publication date
US20080057003A1 (en) 2008-03-06
JP2004523594A (ja) 2004-08-05
EP1372610B1 (en) 2012-05-09
CA2440010A1 (en) 2002-10-17
US20030007932A1 (en) 2003-01-09
ATE556704T1 (de) 2012-05-15
EP1372610A2 (en) 2004-01-02
WO2002080884A2 (en) 2002-10-17
CA2440010C (en) 2012-07-10
UY27218A1 (es) 2002-10-31
AU2002316820A1 (en) 2002-10-21
MXPA03008398A (es) 2004-01-29
US20050196346A1 (en) 2005-09-08
WO2002080884A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
GB0107106D0 (en) Powder inhaler formulations
DE60104399D1 (de) Pulverformulierung zur inhalation
NO20015082D0 (no) Pulverinnåndingsapparat for kombinert medikament
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
DK1173243T3 (da) Pulverinhalator til kombineret medikament
EG23775A (en) Novel dry powder inhalation system for transpulmonary administration
BR9306112A (pt) Separador para inaladores de pó
AU2002311213A1 (en) Dry powder inhalation system for transpulmonary administration
WO2003077825A3 (en) Site specific delivery of co-administered drugs via inhalation
CR10112A (es) Enmascaramiento del sabor de polvos.
WO2004017918A8 (en) Method of preparing dry powder inhalation compositions
WO2002051389A3 (en) Aerogel powder comprising therapeutic agents
IL150528A0 (en) Ibuprofen containing active agent preparation
DE60135099D1 (de) Pulverinhalator
SE0200657D0 (sv) Novel Formulation
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
WO2004062640A3 (de) Kapsel zur aufnahme eines inhalativ applizierbaren wirkstoffs
ZA200309550B (en) Dry powder inhalation system for transpulmonary administration
AP2008004396A0 (en) Dry Powder inhalation system for transpulmonary administration
AU2002355638A1 (en) Flat, oral dosage form comprising particles containing active ingredients
MXPA01011964A (es) Forma de unidad de dosis farmaceutica del tipo de capsulas rigidas que contiene clonixinato de lisina, procedimiento para su preparacion y el uso de dicha unidad de dosis como analgesico y7o antiinflamatorio.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)